TY - JOUR. T1 - Cantharidin-induced cytotoxicity and cyclooxygenase 2 expression in human bladder carcinoma cell line. AU - Huan, Steven Kuan Hua. AU - Lee, Hao Hsien. AU - Liu, Der Zen. AU - Wu, Chien Chih. AU - Wang, Ching Chiung. PY - 2006/6/1. Y1 - 2006/6/1. N2 - Mylabris is used in clinical therapy, but is always accompanied by cystitis. The toxic effects of mylabris on bladder are attributed to its active principle: cantharidin. In the present study, we explored how cantharidin induces cytotoxicity in the bladder. Human bladder carcinoma cell line T 24 cells were used as target cells, and human colon carcinoma HT 29 cells as native cells. Cantharidin exhibited acute cytotoxicity in the T 24 cells, and IC50 was 21.8, 11.2 and 4.6 μM after treatment for 6, 24 and 48 h, respectively. The cytotoxicity of cantharidin was not significantly enhanced when T 24 cells were treated for a longer time. Moreover, PARP proteins and pro-caspase 3, Bcl-2 were significantly inhibited after cantharidin ...

TY - JOUR. T1 - Granulocyte-colony stimulating factor receptor expression on human transitional cell carcinoma of the bladder. AU - Tachibana, Masaaki. AU - Miyakawa, Ayako. AU - Uchida, Atsushi. AU - Sumitomo, Makoto. AU - Nakamura, Kayoko. AU - Murai, Masaru. PY - 1997/12/1. Y1 - 1997/12/1. N2 - Receptors for granulocyte-colony stimulating factor (G-CSFR) have been confirmed on the cell surfaces of several nonhaematopoietic cell types, including bladder cancer cells. This observation has naturally led to the hypothesis that the expression of G-CSFR on these cells may enhance their growth by G-CSF. In this study, the expression of G-CSFR was determined both in established human bladder cancer cell lines and primary bladder cancers. We studied five different human bladder cancer cell lines (KU-1, KU-7, T-24, NBT-2 and KK) and 26 newly diagnosed bladder tumors. G-CSFR mRNA expressions on cultured cell lines were determined using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. ...

U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03113266) titled Safety and Efficacy of JS001 for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma on April 6. Brief Summary: This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial carcinoma who have failed in routine systemic treatment. Study Start Date: Study Type: Interventional Condition: Bladder Urothelial Carcinoma Intervention: Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically. Other Name: JS001 Recruitment Status: Recruiting Sponsor: Shanghai Junshi ...

TY - JOUR. T1 - The effect of mitomycin C on superficial bladder cancer. AU - Soloway, M. S.. AU - Murphy, W. M.. AU - DeFuria, M. D.. AU - Crooke, S.. AU - Finebaum, P.. PY - 1981/1/1. Y1 - 1981/1/1. N2 - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer (stages O and A). Cystoscopically documented tumor was destroyed completely in 11 patients (69 per cent), while 3 patients exhibited partial tumor regression. Two patients had only multifocal, grade 3 carcinoma in situ and both had a complete response with negative biopsies and cytology at the 12-week evaluation. Toxicity was minimal. Further data, including longer followup, are needed to define the potentially promising role of this agent in the over-all management of superficial bladder cancer.. AB - A course of intravesical mitomycin C, consisting of 8 weekly doses of 30 or 40 mg., was evaluated in 16 patients with superficial bladder cancer ...

Fresh, superficial transitional cell carcinomas (TCCs) of low-grade atypia (3 grade I, Ta; 6 grade II, Ta), as well as primary cultures derived from them were labeled with [35S]methionine for 16 h, between 2 and 6 days after inoculation. Whole protein extracts were subjected to IEF (isoelectric focu …

TY - JOUR. T1 - Analysis of matrix metalloproteinase expression in the recurrence of superficial low grade urothelial bladder cancer. AU - Choi, Young Deuk. AU - Ahn, Hyun Soo. AU - Cho, Nam Hoon. AU - Lee, Mee Kyung. AU - Kang, Sook Hee. AU - Yang, Won Jae. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2005/4. Y1 - 2005/4. N2 - Purpose: Superficial bladder transitional cell carcinomas (TCCa) have high recurrence rates following endoscopic resection. Most of the parameters used for the prediction of a recurrence are associated with high grade TCCa. However, there are few valid parameters for prediction of the recurrence of low grade TCCa. We aimed to elucidate the prime factor of a recurrence of superficial low grade bladder TCCa. Materials and methods: Thirty cases of superficial low grade bladder TCCa were analyzed, 15 of which were recurred cases. Fresh frozen tumor and normal tissues were used for the analysis. Real-time reverse transcriptase polymerase chain ...

Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) is used to prevent recurrence and/or progression. However, BCG immunotherapy is associated with significant adverse events and treatment failure may occur in 30-40% of cases, hence the necessity for alternative therapies. In an orthotopic MB49 mouse bladder cancer model, another bacterial vaccine (Ty21a/Vivotif) turned out to be more effective than BCG for inducing tumor regression and mice survival upon intravesical instillation; and potentially safer because Ty21a bacteria did not infect/persist in any mice tissues nor in human bladder explants or cell lines, in contrast to BCG. Ty21a/Vivotif has been used in the last 30 years in millions of individuals as an oral typhoid vaccine with a high safety record. ...

Request a copy of Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer., a 21st Century Oncology physician publication.

Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure Academic Article ...

Prior studies well established that urothelial carcinoma harbors remarkable propensity for divergent differentiation [12-14]. Squamous differentiation has been suggested to be the most common histological variation in bladder urothelial carcinoma and it may present basaloid or clear cell features [15]. However, mechanisms of squamous differentiation in urothelial carcinoma is not very clear. In 1925, Wolbach and Howe found that long time vitamin A deficiency treatment could lead to bladder squamous differentiation in rats [16]. More recently, several findings together with previous studies on the development of squamous differentiation under condition of retinoid deficiency, strongly recommend that retinoid signaling pathways and related networks are significant in the development of squamous lesions in the urinary bladder [17-20]. Maraver et al. showed that downregulation of NOTCH signaling contributed to occurrence of aggression in squamous lesions [21, 22]. Some transcriptional regulators ...

TY - JOUR. T1 - Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. T2 - Clinical Genitourinary Cancer. AU - Rosiello, G.. AU - Knipper, S.. AU - Palumbo, C.. AU - Pecoraro, A.. AU - Luzzago, S.. AU - Deuker, M.. AU - Tian, Z.. AU - Gandaglia, G.. AU - Gallina, A.. AU - Montorsi, F.. AU - Shariat, S.F.. AU - Saad, F.. AU - Briganti, A.. AU - Karakiewicz, P.I.. N1 - Cited By :1 Export Date: 11 March 2021 Correspondence Address: Rosiello, G.; Department of Urology and Division of Experimental Oncology, Via Olgettina, Italy; email: [email protected]. PY - 2020. Y1 - 2020. N2 - Background: Our objective was to test whether the rates of perioperative chemotherapy (CHT) administration in patients with urothelial bladder cancer (UCUB) with prostatic stromal invasion (pT4a) changed over time. Moreover, we tested the effect of CHT on overall mortality (OM), as well as on cancer-specific ...

Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was

TY - JOUR. T1 - The use of regenerative medicine in the management of invasive bladder cancer. AU - Hyndman, Matthew E.. AU - Kaye, Deborah. AU - Field, Nicholas C.. AU - Lawson, Keith A.. AU - Smith, Norm D.. AU - Steinberg, Gary D.. AU - Schoenberg, Mark P.. AU - Bivalacqua, Trinity J.. PY - 2012. Y1 - 2012. N2 - Muscle invasive and recurrent nonmuscle invasive bladder cancers have been traditionally treated with a radical cystectomy and urinary diversion. The urinary diversion is generally accomplished through the creation of an incontinent ileal conduit, continent catheterizable reservoir, or orthotopic neobladder utilizing small or large intestine. While radical extirpation of the bladder is often successful from an oncological perspective, there is a significant morbidity associated with enteric interposition within the genitourinary tract. Therefore, there is a great opportunity to decrease the morbidity of the surgical management of bladder cancer through utilization of novel ...

Despite local therapies, commonly transurethral resection (TUR) followed by adjuvant treatments, non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence and progression. Intravesical Bacillus Calmette-Guérin (BCG) has been shown to reduce recurrence and progression in people with NMIBC following TUR, however many people do not respond to treatment, have recurrence shortly after, or cannot tolerate standard-dose therapy. The potential for synergistic antitumour activity of interferon (IFN)-alpha (α) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy. To assess the effects of intravesically administered BCG plus IFN-α compared with BCG alone for treating non-muscle-invasive bladder cancer. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8, 2016), MEDLINE (OvidSP) (1946 to 2016), Embase (OvidSP) (1974 to 2016), ClinicalTrials.gov, the World Health Organization ...

Is it time for urologists to begin to rethink the radical cystectomy and begin to explore trimodality therapy? Maybe - maybe not - it depends on who you ask. Lets go over a few things first, though, before we jump right in.. (TMT) Trimodality Therapy is not some radical new line of treatment. The Tri stands for three modalities of treatment: chemotherapy, radiotherapy, and surgery. And again, while nothing new, the treatments used in combination to fight bladder cancer are a course of treatment that allows the patient to keep their bladder rather than have it removed.. (RC) Radical Cystectomy is typically the removal of the entire bladder, lymph nodes in proximity to the bladder, part of the urethra, and any organ tissue in proximity that does or could have cancerous cells.. For women, it can - but not always - entail uterus, ovaries, fallopian tubes, and part of the vagina being removed.. For men, it can - but not always - entail prostate, seminal vesicles, part of the vas deferens being ...

A previously completed pivotal clinical study PC B305/04 demonstrated reduced recurrence rates for patients with papillary bladder cancer who underwent Hexvix (Cysview) and white light cystoscopy and transurethral resection (TURB) of the bladder compared to patients who underwent white light cystoscopy and TURB alone.. The present study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will also lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.. No safety data was collected. ...

TY - JOUR. T1 - Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma. T2 - A matched cohort analysis. AU - Wang, Jeffrey K.. AU - Boorjian, Stephen A.. AU - Cheville, John C.. AU - Kim, Simon P.. AU - Tarrell, Robert F.. AU - Thapa, Prabin. AU - Frank, Igor. PY - 2012/12/1. Y1 - 2012/12/1. N2 - Purpose: Micropapillary (MP) bladder cancer is a rare variant of urothelial carcinoma (UC) which has been associated with an aggressive natural history. We sought to report the outcomes of patients with MP bladder cancer treated with radical cystectomy (RC) and compare survival to patients with pure UC of the bladder. Methods: We identified 73 patients with MP bladder cancer and 748 patients with pure UC who underwent RC at our institution with median postoperative follow-up of 9.6 years. MP patients were stage-matched 1:2 to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Results: MP ...

Supplementary Materials? JCMM-23-3905-s001. findings suggest BZW2 comes with an oncogenic part in MIBCs and acts as a guaranteeing focus on for molecular diagnosis and gene therapy. strong class=kwd-title Keywords: BZW2, microarray pathway analysis, muscle\invasive bladder cancers (MIBCs), xenograft model 1.?INTRODUCTION Bladder cancer is among the most common cancers all over the world, with approximately 380,000 new cases and 150,000 deaths per year.1 It ranks fifth among cancers in men in western countries.2 Tfpi Age is the most significant risk factor for bladder cancer, and median age at diagnosis is about 70?years.3 Bladder cancer poses a considerable economic burden primarily Orphenadrine citrate owing to the lifetime surveillance and repeated treatment of recurrent disease.4 According to the extent of invasion, it consists of muscle\invasive bladder cancers (MIBCs) and non\muscle\invasive bladder cancers (NMIBCs). Although only 20% of bladder cancer patients are diagnosed with MIBCs, ...

Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...

Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...

PURPOSE: Salvage cystoprostatectomy has evolved as a safe and potentially curative treatment option for patients with radiation recurrent bladder cancer. Although orthotopic bladder replacement remains the preferred form of urinary diversion, there is minimal information about its role in salvage cystectomy series. We describe our limited experience in this regard. MATERIAL AND METHODS: We evaluated the operative characteristics and outcome of two patients with muscle invasive transitional cell carcinoma (TCC) of the urinary bladder after failed high-dose radiation therapy (mean 6,490 cGy). Both patients underwent salvage cystoprostatectomy with Studer-type ileal neobladder reconstruction. Existing literature on the topic is reviewed. RESULTS: Final histopathology showed pT3 N0 M0 TCC urinary bladder with no recent evidence of tumor recurrence. There was no mortality or major perioperative complication. Mean surgery time was 590 minutes, and mean blood loss was 1,600 mL, with 3.5 U of packed cell

A look at the following clinical trial: Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery.

We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...

We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...

Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...

Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...

The sensitivity of flow cytometry compared with conventional cytology in the detection of superficial bladder carcinoma Academic Article Article ...

TY - JOUR. T1 - Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. AU - Kluth, Luis A.. AU - Xylinas, Evanguelos. AU - Crivelli, Joseph J.. AU - Passoni, Niccolo. AU - Comploj, Evi. AU - Pycha, Armin. AU - Chrystal, James. AU - Sun, Maxine. AU - Karakiewicz, Pierre I.. AU - Gontero, Paolo. AU - Lotan, Yair. AU - Chun, Felix K H. AU - Fisch, Margit. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. PY - 2013/8. Y1 - 2013/8. N2 - Purpose: To our knowledge the impact of body mass index on oncologic outcomes in nonmuscle invasive bladder cancer has not been evaluated. We hypothesized that higher body mass index is associated with worse outcomes in patients with clinical primary T1 high grade urothelial carcinoma of the bladder. Materials and Methods: We retrospectively analyzed data from 892 patients with primary nonmuscle invasive bladder cancer from 7 centers. Patients were treated with transurethral resection of the bladder with or ...

Background This study aimed to judge the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or both drugs to untreated ones. high stage disease (T1) attained the amount of unbiased risk aspect for the incident of the recurrence. When sufferers were stratified based on the different treatment; sufferers treated with statins (Group B) provided an higher level of failing (56/91 sufferers; 61.5%) in comparison with Group A (42/98 sufferers; 42.9%), Group C (56/98; 57.1%) and (133/287 sufferers; 46.3%). This difference corresponds to a big change in recurrence failing free success (p?=?0.01). Conclusions Our outcomes claim that long-term treatment with aspirin in sufferers with NMIBC might are likely involved on reducing the chance of tumor recurrence. On the other hand, in our analysis data from statins and mixture treatment groups demonstrated increased recurrence prices. ...

TY - JOUR. T1 - The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. AU - Mitra, Anirban P.. AU - Almal, Arpit A.. AU - George, Ben. AU - Fry, David W.. AU - Lenehan, Peter F.. AU - Pagliarulo, Vincenzo. AU - Cote, Richard J.. AU - Datar, Ram H.. AU - Worzel, William P.. N1 - Copyright: Copyright 2013 Elsevier B.V., All rights reserved.. PY - 2006/6/16. Y1 - 2006/6/16. N2 - Background: Previous studies on bladder cancer have shown nodal involvement to be an independent indicator of prognosis and survival. This study aimed at developing an objective method for detection of nodal metastasis from molecular profiles of primary urothelial carcinoma tissues. Methods: The study included primary bladder tumor tissues from 60 patients across different stages and 5 control tissues of normal urothelium. The entire cohort was divided into training and validation sets comprised of node positive and node negative ...

Background The rationale for combining anticancer drugs has not been applied consistently to use of intravesical agents for treatment of superficial bladder cancer, for which immunotherapeutic BCG and chemotherapeutic mitomycin seem to be a potentially effective combination. We aimed to do a prospective, randomised comparison of BCG alone with that of sequential BCG and electromotive mitomycin in patients with stage pT1 bladder cancer. Methods After transurethral resection and multiple biopsies, 212 patients with stage pT1 bladder cancer were randomly assigned to: 81 mg BCG infused over 120 min once a week for 6 weeks (n=105); or to 81 mg BCG infused over 120 min once a week for 2 weeks, followed by 40 mg electromotive mitomycin (intravesical electric current 20 mA for 30 min) once a week as one cycle for three cycles (n=107). Complete responders underwent maintenance treatment: those assigned BCG alone had one infusion of 81 mg BCG once a month for 10 months, and those assigned BCG and ...

TY - JOUR. T1 - Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. AU - Shiota, Masaki. AU - Takeuchi, Ario. AU - Yokomizo, Akira. AU - Kashiwagi, Eiji. AU - Tatsugami, Katsunori. AU - Kuroiwa, Kentaro. AU - Naito, Seiji. PY - 2012/7. Y1 - 2012/7. N2 - Purpose: There are several reports of androgen receptor in bladder cancer cases but androgen receptor expression and the function of androgen/androgen receptor signaling in bladder cancer remain unclear. We investigated androgen receptor expression and the role of androgen/androgen receptor signaling in bladder cancer. Materials and Methods: We evaluated AR mRNA expression in bladder cancer tissue by quantitative real-time polymerase chain reaction. The role of androgen receptor in cell growth and drug sensitivity was also evaluated in vitro and in vivo in several bladder cancer cell lines. Results: AR mRNA expression inversely correlated with bladder cancer grade, stage and spread. Of several ...

Lutheran/basal cell adhesion molecule (Lu/BCAM) is a membrane bound glycoprotein. This study was performed to investigate the role and downstream signaling pathway of Lu/BCAM in human bladder tumorigenesis. Five human bladder cancer (E6, RT4, TSGH8301, TCCSUP and J82), one stable mouse fibroblast cell line (NIH-Lu) expressing Lu/BCAM transgene and sixty human uroepithelial carcinoma specimens were analyzed by real-time PCR, immunohistochemistry (IHC), immunofluorescence (IFA) staining, Western blotting and promoter luciferase assay for Lu/BCAM, respectively. The tumorigenicity of Lu/BCAM was demonstrated by focus formation, colony-forming ability, tumour formation, cell adhesion and migration. H-ras V12 was revealed to up-regulate Lu/BCAM at both transcriptional and translation levels. Lu/BCAM expression was detected on the membrane of primary human bladder cancer cells. Over-expression of Lu/BCAM in NIH-Lu stable cells increased focus

OBJECTIVES To assess the efficacy of nuclear matrix protein 22 (NMP-22) in the diagnosis of recurrent, superficial bladder cancer and whether it can predict for future recurrence. METHODS Patients with diagnosed and treated superficial transitional cell carcinoma urinary bladder (Stage Ta, T1, Tis, Nx, and M0) presenting for surveillance follow-up were prospectively enrolled in this study from February 2004 to August 2005. These patients underwent urine cytology, NMP-22 testing, and cystopanendoscopy on enrollment in the study. For the next year, these patients underwent cystopanendoscopy and cytology at 3-month intervals. The ability of NMP-22 to predict for recurrence was determined using the cystoscopy findings as the reference standard. RESULTS A total of 145 patients were included in the study. Of these, 56 had recurrence at enrollment. Of the 56 patients, 48 had positive NMP-22 findings and 22 had positive urine cytology findings. The sensitivity, specificity, positive predictive value, and

Bladder cancer treatment is dependent on the depth of invasion through the bladder wall. Superficial bladder cancers are treated by resection through the urethra, known as transurethral resection of bladder tumor (TURBT). Under general anesthesia, a scope is inserted into the urethra to navigate the anatomic tube through which the urine exits the body.For bladder cancer that invades into the muscle of the bladder wall, the gold standard therapy is surgical removal of the entire bladder (radical cystectomy), and dissection of a lymph node to detect whether cancer has spread beyond the bladder. In men, the prostate and seminal vesicles are also removed. Bladder replacement options are performed with the use of an intestinal segment and are classified as either: (1) incontinent or (2) continent.An incontinent diversion (ileal conduit) requires a bag to be placed over a stoma to capture urine that drains as it is produced.A continent diversion stores urine and comes in two types: (1) neobladder or (2)

http://www.statistik.at/web_de/statistik... ). The optimal management of geriatric patients with invasive bladder cancer will increasingly become an important issue. In younger patients with MIBC, RC remains the gold standard of therapy (33. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al.: Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21: 690-6.,1212. Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A, et al.: 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol. 1998; 33(Suppl 4): 25-6.). However, geriatric patients have a higher number of relevant comorbidities resulting in an enhanced surgical risk. Prout et al. (1313. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK: Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer. 2005; 104: 1638-47.) reported ...

MeSH-minor] Brachytherapy. Combined Modality Therapy. Controlled Clinical Trials as Topic. Cystectomy. Data Interpretation, Statistical. Dose Fractionation. Female. Humans. Kidney / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / surgery. Male. Meta-Analysis as Topic. Neoplasm Staging. Nephrectomy. Organ Preservation. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Ureter / pathology. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / radiotherapy. Urethra / pathology. Urethral Neoplasms / drug therapy. Urethral Neoplasms / mortality. Urethral Neoplasms / pathology. Urethral Neoplasms / radiotherapy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / ...

Highlights: Black-Right-Pointing-Pointer The tumor suppressor gene PDCD4 is down-regulated in many tumorous entities. Black-Right-Pointing-Pointer We investigate the impact of PDCD4 and its regulating factor miR-21 in urothelial carcinoma. Black-Right-Pointing-Pointer We confirm PDCD4 as a tumor suppressor gene and it could be a diagnostic marker for this tumor. -- Abstract: Background: We investigated the role of the programmed cell death 4 (PDCD4) tumor suppressor gene in specimens of transitional cell carcinoma and of healthy individuals. Methods: PDCD4 immunohistochemical expression was investigated in 294 cases in histologically proven transitional cell carcinoma in different tumorous stages (28 controls, 122 non-muscle invasive urothelial carcinoma, stages Tis-T1, 119 invasive transitional cell carcinoma stages T2-T4 and 25 metastases). MiR-21 expression, an important PDCD4 regulator, was assessed with real-time PCR analysis and showed inverse correlation to tissue PDCD4 expression. ...

Spectrum of computed tomography findings in gall bladder carcinoma patients: a retrospective observational study from tertiary care oncology setup

Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non-muscle-invasive bladder cancer. Primary producers of BCG announced shortages within the last decade, leading to a worldwide shortage. We review the literature examining the BCG shortage and propose solutions to cope with this problem.

Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the...

Abstract Bladder cancer is one of the most common malignancies and causes hundreds of thousands of deaths worldwide each year. Bladder cancer is strongly associated with exposure to environmental carcinogens. It is believed that DNA damage generated by environmental carcinogens and their metabolites causes development of bladder cancer. Nucleotide excision repair (NER) is the major DNA repair pathway for repairing bulk DNA damage generated by most environmental carcinogens, and XPC is a DNA damage recognition protein required for initiation of the NER process. Recent studies demonstrate reduced levels of XPC protein in tumors for a majority of bladder cancer patients. In this work we investigated the role of histone deacetylases (HDACs) in XPC gene silencing and bladder cancer development. The results of our HDAC inhibition study revealed that the treatment of HTB4 and HTB9 bladder cancer cells with the HDAC inhibitor valproic acid (VPA) caused an increase in transcription of the XPC gene in these cells

SIU 2019 intravesical therapy for non-muscle invasive bladder cancer, BCG treatment, Hyperthermic intravesical chemotherapy, TURBT, KEYNOTE 057 trial, VISTA trial, gemcitabine and docetaxel, NMIBC patients, Instiladrin, Nadofaragene firadenovec, Adstiladrin

Cheapest Transurethral Resection Of Bladder Tumor TURBT price in Cuttack, India is $. Average Transurethral Resection Of Bladder Tumor TURBT cost $0, where prices can go as high as $. PlacidWay Medical Tourism provides cost comparison for Transurethral Resection Of Bladder Tumor TURBT, Urology Prices in Cuttack, India. Explore Transurethral Resection Of Bladder Tumor TURBT prices worldwide.

The urogenous-contact hypothesis proposes that the development of bladder cancer is associated with prolonged exposure to carcinogens in urine. To fully examine this hypothesis, this dissertation systematically addressed fluid intake, micturition habits, associated medical conditions, and medications in relation to risk of bladder cancer in the Los Angeles Bladder Cancer Case-Control Study.; Total fluid intake was not associated with risk of bladder cancer, but specific types of beverages had different influence on bladder cancer. Consumption of water and alcoholic beverages were associated with a reduced risk of bladder cancer, whereas consumption of coffee was associated with a slightly increased risk, especially among heavy drinkers. The alcohol-bladder cancer association was modified by genetic variations in glutathione S-transferases, and the coffee-bladder cancer association was modified by variations in N-acetyltransferase 2 and cytochrome P450 1A2.; This dissertation also examined the ...

Tobacco consumption has been implicated as the most relevant risk factor for the development of bladder cancer. Among various carcinogens identified in tobacco smoke, the polycyclic aromatic hydrocarbons (PAHs) are well characterized and their risk associations with bladder cancer are well studied [1-4]. In addition to these strong environmental risk factors, recent genome-wide association studies have identified several highly significant genetic factors with small effects [5, 6]. Some of these have been shown to modify the effects of smoking on risk of bladder cancer [7].. Most existing genetic association studies have focused on the independent effects of individual genes. That is, they have by design ignored the context of human ecology and the extensive variability in the human genome. As a result, much of the heritability of common human diseases such as bladder cancer remains unexplained. Multiple approaches have been proposed to account for this missing heritability including sequencing ...

TY - JOUR. T1 - Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. AU - Klatte, Tobias. AU - Xylinas, Evanguelos. AU - Rieken, Malte. AU - Kluth, Luis A.. AU - Rouprêt, Morgan. AU - Pycha, Armin. AU - Fajkovic, Harun. AU - Seitz, Christian. AU - Karakiewicz, Pierre I.. AU - Lotan, Yair. AU - Babjuk, Marko. AU - De Martino, Michela. AU - Scherr, Douglas S.. AU - Shariat, Shahrokh F.. N1 - Copyright: Copyright 2014 Elsevier B.V., All rights reserved.. PY - 2014/5. Y1 - 2014/5. N2 - Purpose ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder ...

TY - JOUR. T1 - Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. AU - Sahu, Divya. AU - Lotan, Yair. AU - Wittmann, Bryan. AU - Neri, Bruce. AU - Hansel, Donna E.. N1 - Funding Information: This work was supported by the Case Western Reserve University/Cleveland Clinic CTSA Grant Number UL1 RR024989 from the National Center for Research Resources (NCRR) and a KL2 career development award (RR024990) to D.E.H., as well as a Prevent Cancer Foundation Fellowship Award to D.S. Publisher Copyright: © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2017/9. Y1 - 2017/9. N2 - Urothelial carcinoma is the most common form of bladder cancer, but pathway changes that occur with stage-wise progression have not been well defined. We used a metabolomics approach to identify potential metabolic pathways uniquely altered in normal urothelium, nonmuscle-invasive ...

Treatment options vary with the location of the tumor, but in general, require surgical excision. Installation of bacille Calmette-Guerin (BCG) or mitomycin C may be used in selected cases as an alternative to surgery in some cases .. A critical part of the management of patients with transitional cell carcinomas is an awareness of the high rate of recurrence due to a field effect on the urothelium. Approximately 40% of patients with an upper urinary tract transitional cell carcinoma will go on to develop one or more TCCs of the bladder, and approximately 2-4% of patients with a bladder transitional cell carcinoma will go on to develop one or more TCCs of the renal pelvis or ureter .. ...

Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.

Looking for online definition of cystitis glandularis in the Medical Dictionary? cystitis glandularis explanation free. What is cystitis glandularis? Meaning of cystitis glandularis medical term. What does cystitis glandularis mean?

TY - JOUR. T1 - Oncological and functional outcomes of robotassisted radical cystectomy in bladder cancer patients in a single tertiary center. T2 - Can these be preserved throughout the learning curve?. AU - Tae, Jong Hyun. AU - Pyun, Jong Hyun. AU - Shim, Ji Sung. AU - Cho, Seok. AU - Kang, Sung Gu. AU - Ko, Young Hwii. AU - Cheon, Jun. AU - Lee, Jeong Gu. AU - Kang, Seok Ho. N1 - Funding Information: This research was supported by a grant of Korea University Medical Center and Anam Hospital, Seoul, Korea. Publisher Copyright: © The Korean Urological Association.. PY - 2019/11. Y1 - 2019/11. N2 - Purpose: To evaluate the overall and segmental oncological and functional outcome of robot-assisted radical cystectomy (RARC) during the learning curve. Materials and Methods: From August 2007 to November 2017, a total of 120 bladder cancer patients were treated with RARC in a single-tertiary hospital. These were divided into three groups of 40 consecutive cases. Overall and subgroup analysis of each ...

TY - JOUR. T1 - Carcinosarcoma of bladder following long-term cyclophosphamide therapy. AU - Sigal, S. H.. AU - Tomaszewski, J. E.. AU - Brooks, J. J.. AU - Wein, A.. AU - LiVolsi, V. A.. PY - 1991/1/1. Y1 - 1991/1/1. N2 - Since the advent of long-term cyclophosphamide therapy, an association between this agent and the subsequent development of bladder neoplasms has been documented. Only six sarcomas have been reported, to our knowledge. This report describes the first case in which a leiomyosarcoma and an invasive transitional cell carcinoma (ie, carcinosarcoma) developed in a patient with non-Hodgkins lymphoma treated with 240 g of cyclophosphamide over a 6.5-year period.. AB - Since the advent of long-term cyclophosphamide therapy, an association between this agent and the subsequent development of bladder neoplasms has been documented. Only six sarcomas have been reported, to our knowledge. This report describes the first case in which a leiomyosarcoma and an invasive transitional cell ...

In urologic pathology, PUNLMP, short for papillary urothelial neoplasm of low malignant potential, is an exophytic (outward growing), (microscopically) nipple-shaped (or papillary) pre-malignant growth of the lining of the upper genitourinary tract (the urothelium), which includes the renal pelvis, ureters, urinary bladder and part of the urethra. PUNLMP is pronounced pun-lump, like the words pun and lump. As their name suggests, PUNLMPs are neoplasms, i.e. clonal cellular proliferations, that are thought to have a low probability of developing into urothelial cancer, i.e. a malignancy such as bladder cancer. PUNLMPs can lead to blood in the urine (hematuria) or may be asymptomatic. PUNLMPs are exophytic lesions that appear friable to the naked eye and when imaged during cystoscopy. They are definitively diagnosed after removal by microscopic examination by pathologists. Histologically, they have a papillary architecture with slender fibrovascular cores and rare basal mitoses. The papillae ...

P.I.: Satia, Jessie A Department: Nutrition and Epidemiology Title: Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A Randomized Trial

Three genome-wide association studies in Europe and the USA have reported eight urinary bladder cancer (UBC) susceptibility loci. Using extended case and control series and 1000 Genomes imputations of 5 340 737 single-nucleotide polymorphisms (SNPs), we searched for additional loci in the European GWAS. The discovery sample set consisted of 1631 cases and 3822 controls from the Netherlands and 603 cases and 37 781 controls from Iceland. For follow-up, we used 3790 cases and 7507 controls from 13 sample sets of European and Iranian ancestry. Based on the discovery analysis, we followed up signals in the urea transporter (UT) gene SLC14A. The strongest signal at this locus was represented by a SNP in intron 3, rs17674580, that reached genome-wide significance in the overall analysis of the discovery and follow-up groups: odds ratio = 1.17, P = 7.6 x 10(-11). SLC14A1 codes for UTs that define the Kidd blood group and are crucial for the maintenance of a constant urea concentration gradient in the ...

In order to understand the origin of bladder cancer, very early urothelial lesions must be investigated in addition to more advanced tumors. Tissue from 31 biopsies of 12 patients with urothelial hyperplasias and simultaneous or consecutive superficial papillary tumors were used to microdissect urothelium from 15- microm sections of biopsies. The biopsies were obtained with the recently developed highly sensitive diagnostic method of 5-aminolevulinic acid-induced fluorescence endoscopy (AFE). Besides flat and papillary urothelial neoplasms, the method of photodynamic diagnostics also detects simple urothelial hyperplasias as fluorescent positive lesions. In addition, 12 fluorescence-positive biopsies showing histologically normal urothelium were investigated. Fluorescence in situ hybridization was done using a dual color staining technique of biotinylated centromeric probes of chromosomes 9 and 17 and digoxigenin-labeled gene-specific P1 probes for chromosomes 9q22 (FACC), 9p21(p16/CDKI2), and ...

TY - JOUR. T1 - Stage progression in Ta papillary urothelial tumors. T2 - Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. AU - Holmäng, S.. AU - Andius, P.. AU - Hedelin, H.. AU - Wester, K.. AU - Busch, C.. AU - Johansson, S. L.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - Purpose: We studied 363 patients with stage Ta bladder tumors during long-term followup who were classified according to the 1998 WHO and International Society of Urological Pathology consensus classifications. We determine whether various immunohistochemical and molecular markers could predict tumor progression. Materials and Methods: A total of 680 patients in western Sweden with a first diagnosis of bladder carcinoma in 1987 and 1988 were registered and followed for at least 5 years. There were 363 (53%) tumors that were papillary stage pTa. The tumors were classified as papillary urothelial neoplasm of low malignant potential in 95 patients, low grade papillary urothelial ...

TY - JOUR. T1 - Collaboration of RON and Epidermal Growth Factor Receptor in Human Bladder Carcinogenesis. AU - Hsu, Pei Yin. AU - Liu, Hsiao Sheng. AU - Cheng, Hong Lin. AU - Tzai, Tzong Shin. AU - Guo, How Ran. AU - Ho, Chung Liang. AU - Chow, Nan Haw. PY - 2006/11. Y1 - 2006/11. N2 - Purpose: Collaboration of heterologous receptor tyrosine kinases has emerged as an important paradigm in tumor progression. We recently proved that RON has an important role in human bladder carcinogenesis. Since epidermal growth factor receptor has been suggested to cross-talk with RON, we examined the significance of epidermal growth factor receptor in modulating RON associated tumorigenesis. Materials and Methods: The biological significance of collaboration between RON and epidermal growth factor receptor was examined in the TSGH8301, J82 and JR bladder cancer cell lines with different expression status. Immunoprecipitation and immunoblotting assays were done to investigate the interaction of RON with ...

This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Cribriform-morular variant of papillary thyroid carcinoma at pediatric age - case report to the diagnosis of ovarian dermoid cyst associated with papillary urothelial malignant cystadenoma.

The recent study by Rosenberg et al in The Lancet-summarized in this issue of The ASCO Post-is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the investigational programmed cell death ligand 1 (PD-L1) antibody atezolizumab.. Based on objective response rate and low level of toxicity, atezolizumab appears to be superior to all other current single agents used in second-line therapy for transitional cell carcinoma. Moreover, the trial reported by Rosenberg et al strongly confirms the activity of atezolizumab seen in the phase Ib trial of Powles et al.2. Concordant Studies. In the phase Ib trial, patients were initially selected for entry based on PD-L1 expression of 2 to 3+ on the infiltrating immune cells (IC 2/3) in the tumor (not PD-L1 expression on the tumor cells). A subsequent group of patients with IC 0/1 disease were entered on the trial. In the selected ...

TY - JOUR. T1 - Oncologic surveillance following radical cystectomy. T2 - an individualized risk-based approach. AU - Merrill, Suzanne B.. AU - Boorjian, Stephen A.. AU - Thompson, R. Houston. AU - Psutka, Sarah P.. AU - Cheville, John C.. AU - Thapa, Prabin. AU - Tollefson, Matthew K.. AU - Frank, Igor. PY - 2017/7/6. Y1 - 2017/7/6. N2 - Purpose: To provide an alternative surveillance approach for bladder cancer (BC) following radical cystectomy (RC) according to more accurate predictions of a patients projected BC course. Methods: We identified 1797 patients who underwent RC for M0 BC between 1980 and 2007. Patients were stratified by pathologic stage (pT0Nx-0, pTa/CIS/1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN+), relapse location (urethra, upper tract, abdomen/pelvis, chest, and other), age (≤60, 61-70, 71-80, ,80 years) and Charlson Co-morbidity Index (CCI ≤2 and CCI ≥3). Risks of disease recurrence and non-BC death were modeled using Weibull distributions. Recommended surveillance ...

TY - JOUR. T1 - Transitional cell carcinoma of the renal pelvis with chriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. AU - Grammatico, Dino. AU - Grignon, David J.. AU - Eberwein, Parker. AU - Shepherd, R. Roderick. AU - Hearn, Stephen A.. AU - Walton, John C.. PY - 1993/3/1. Y1 - 1993/3/1. N2 - Background. There have been 12 documented cases of choriocarcinoma arising in the urinary bladder, either alone or in combination with other epithelial tumors. It has been shown that some high‐grade transitional cell carcinomas (TCC), without obvious syncytiotrophoblastic elements, can produce human chorionic gonadotropins (HCG). Methods. A case of choriocarcinoma, in association with high‐grade TCC of the renal pelvis, was encountered in an 80‐year‐old man. For additional evaluation of HCG production by TCC, 25 consecutive cases of invasive ...

Bladder Cancer Biological Therapy India,Cost Biological Therapy India, Bladder Cancer In India Offers Info On Cost Bladder Cancer Surgery India, Bladder Cancer Treatment Hospital Mumbai India, Bladder Cancer Surgeons India Mumbai Bangalore, Bladder Cancer Center India, Bladder Cancer Doctors India

Transurethral Resection of Bladder Cancer (TURBT): Find the most comprehensive real-world treatment information on Transurethral Resection of Bladder Cancer (TURBT) at PatientsLikeMe. 2 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, systemic lupus erythematosus, diabetes type 2, post-traumatic stress disorder, rheumatoid arthritis, bipolar disorder, Parkinsons disease, panic disorder, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, amyotrophic lateral sclerosis, persistent depressive disorder (dysthymia), epilepsy, migraine, hypothyroidism, osteoarthritis, attention deficit/hyperactivity disorder, bipolar II disorder, traumatic brain injury, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or mild depression currently have Transurethral Resection of Bladder Cancer (TURBT).

Orthotopic neo- bladder in women Manlio Schettini Summary Introduction: Radical cystectomy is the most effective treatment madality for high grade urinary bladder carcinoma and orthotopic reconstruction is the better urinary diversion modality also in women. Material and methods: From 2002 to 2007 we performed 14 radical cystectomies followed by orthotopic reconstruction in women aged between 47 and 68 years (mean age 56) affected by urinary bladder carcinoma. Our reconstructive technique requires the preparation of two strips of the recti muscles fascia, the sectioning of the bladder neck and, when the uterus is present, hysteroannessiectomy and cystectomy en block leaving intact the lateral and inferior vaginal walls. The pelvic floor is stabilized by a colposacropexis with a prosthesis and placing an omental flap over the prosthesis The orthotopic reconstruction is achieved via a neobladder according to the Padovana technique. The ureters are anastomized to the neobladder and splinted with ...

TY - JOUR. T1 - Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. AU - Hautmann, S. H.. AU - Lokeshwar, V. B.. AU - Schroeder, G. L.. AU - Civantos, F.. AU - Duncan, R. C.. AU - Gnann, R.. AU - Friedrich, M. G.. AU - Soloway, M. S.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 2001. Y1 - 2001. N2 - Purpose: We examined the expression of 2 bladder tumor markers, hyaluronic acid (HA) and hyaluronidase (HAase), in bladder tissues and correlated tissue staining with the inferences of the HA-HAase urine test, which detects bladder cancer. Materials and Methods: A biotinylated HA binding protein and an antiHYAL1 antibody were used to localize HA and HYAL1 type HAase, respectively, in 83 bladder tissues. Immunoblot analysis was performed using an antiHYAL1 antibody to detect HYAL1. Results: A total of 12 normal bladder tissues showed no (66%) to 1+ (34%) HA staining and 0 (83%) to 1+ (17%) HYAL1 staining. ...

TY - JOUR. T1 - The Need for Interim Assessment of Neoadjuvant Chemotherapy Response for Muscle Invasive Bladder Cancer-Can We Help Prevent Definitive Treatment Delay in Nonresponders?. AU - Regmi, Subodh K.. AU - Kalapara, Arveen. AU - Konety, Badrinath R.. N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine. PY - 2021/2/1. Y1 - 2021/2/1. KW - cystectomy. KW - cystoscopy. KW - neoadjuvant therapy. KW - response evaluation criteria in solid tumors. KW - time-to-treatment. UR - http://www.scopus.com/inward/record.url?scp=85100280721&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85100280721&partnerID=8YFLogxK. U2 - 10.1097/JU.0000000000001381. DO - 10.1097/JU.0000000000001381. M3 - Editorial. C2 - 32945699. AN - SCOPUS:85100280721. VL - 205. SP - 327. EP - 329. JO - Journal of Urology. JF - Journal of Urology. SN - 0022-5347. IS - 2. ER - ...

TY - JOUR. T1 - Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. AU - Thompson, R. Houston. AU - Krambeck, Amy. AU - Lohse, Christine M.. AU - Elliott, Daniel S.. AU - Patterson, David E.. AU - Blute, Michael L.. PY - 2008/11. Y1 - 2008/11. N2 - OBJECTIVE: To report our experience using ureteroscopic or percutaneous management of upper urinary tract (UUT) transitional cell carcinoma (TCC) in patients with no history of bladder TCC. PATIENTS AND METHODS: Between 1983 and 2004 we identified 22 patients who underwent endoscopic management of TCC first diagnosed in the UUT and in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: The median (range) age at diagnosis was 64 (37-86) years and the median tumour size was 0.8 (0.3-2.6) cm. The tumour grade was 1, 2, or diagnosed as visual low grade in two (9%), seven (32%), and 13 (59%) patients, respectively; no patient ...

Primary signet ring cell carcinoma of urinary bladder is a rare type of bladder tumor and carries a very high mortality rate. It may have a clinical presentation similar to common diseases like Benign Prostatic Hypertrophy (BPH) and the management options are extremely limited. We report a case of 58 year old Caucasian male who presented with a 5 month history of increased frequency of urination, nocturia and weight loss without any fever or hematuria. He was found to have an increased creatinine of 2.8 mg/dl and a prostate specific antigen level of 0.18 ng/ml. His azotemia was thought to be secondary to BPH. A foley catheter was initially placed with a plan for outpatient follow up. On removal of the catheter his problems persisted and he returned to the hospital. Diagnostic work up including abdominal ultrasonography, computed tomography (CT) scan, retrograde pyelogram, cystography and cystoscopic biopsies revealed the diagnosis of primary signet ring cell carcinoma of urinary bladder. Although

Transitional cell cancer of the renal pelvis and ureter is a disease in which malignant (cancer) cells form in the renal pelvis and ureter. The renal pelvis is the top part of the ureter. The ureter is a long tube that connects the kidney to the bladder. There are two kidneys, one on each side of the backbone, above the...

TY - JOUR. T1 - Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. AU - Wheat, Jeffery C.. AU - Weizer, Alon Z.. AU - Wolf, J. Stuart. AU - Lotan, Yair. AU - Remzi, Mesut. AU - Margulis, Vitaly. AU - Wood, Christopher G.. AU - Montorsi, Francesco. AU - Roscigno, Marco. AU - Kikuchi, Eiji. AU - Zigeuner, Richard. AU - Langner, Cord. AU - Bolenz, Christian. AU - Koppie, Theresa M.. AU - Raman, Jay D.. AU - Fernández, Mario. AU - Karakiewizc, Pierre. AU - Capitanio, Umberto. AU - Bensalah, Karim. AU - Patard, Jean Jacques. AU - Shariat, Shahrokh F.. PY - 2012/5. Y1 - 2012/5. N2 - Objective: Carcinoma in situ (CIS) is associated with increased risk of progression when found with high-grade non-muscle-invasive bladder cancer, yet its impact is less clear in the upper urinary tract. In the current study, we evaluated the impact of concomitant CIS on recurrence-free survival and cancer-specific ...

The urinary bladder is the organ that collects urine excreted by the kidneys before disposal by urination. The urinary bladder is a triangular, hollow and distensible (or elastic) organ that is located in the lower abdominal region. Urine enters the bladder via the ureters and exits via the urethra. Bladders occur throughout much of the animal kingdom, but they are very diverse in form and in some cases are not homologous with the urinary bladder in humans. The human urinary bladder is derived in embryo from the urogenital sinus and, it is initially continuous with the allantois. In males, the base of the bladder lies between the rectum and the pubic symphysis. It is superior to the prostate, and separated from the rectum by the rectovesical excavation. In females, the bladder sits inferior to the uterus and anterior to the vagina; thus, its maximum capacity is lower than in males. It is separated from the uterus by the vesicouterine excavation. In infants and young children, the urinary bladder ...

The urinary bladder is the organ that collects urine excreted by the kidneys before disposal by urination. The urinary bladder is a triangular, hollow and distensible (or elastic) organ that is located in the lower abdominal region. Urine enters the bladder via the ureters and exits via the urethra. Bladders occur throughout much of the animal kingdom, but they are very diverse in form and in some cases are not homologous with the urinary bladder in humans. The human urinary bladder is derived in embryo from the urogenital sinus and, it is initially continuous with the allantois. In males, the base of the bladder lies between the rectum and the pubic symphysis. It is superior to the prostate, and separated from the rectum by the rectovesical excavation. In females, the bladder sits inferior to the uterus and anterior to the vagina; thus, its maximum capacity is lower than in males. It is separated from the uterus by the vesicouterine excavation. In infants and young children, the urinary bladder ...

TY - JOUR. T1 - Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. AU - Dalbagni, Guido. AU - Parekh, Dipen J.. AU - Ben-Porat, Leah. AU - Potenzoni, Michele. AU - Herr, Harry W.. AU - Reuter, Victor E.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2007/2. Y1 - 2007/2. N2 - OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The ...

Scottish Terriers are at 18-fold greater risk of developing urinary bladder cancer (invasive transitional cell carcinoma [TCC]) compared with other breeds. TCC is an aggressive tumor, and survival rates are poor. Most TCC of the bladder cannot be removed surgically and is resistant to chemotherapy. The best approach to reduce morbidity and mortality from bladder cancer in Scottish Terriers is to prevent its occurrence. The primary objective this epidemiological study is to identify host (genetic), agent, and environmental factors that increase or decrease the risk of TCC. A case control study is proposed in which Scottish Terriers of comparable ages with or without TCC will be compared. Using medical records and questionnaire responses from owners, the primary risk factors studied will include: (1) exposure to insecticides, particularly the new generation flea control products and lawn chemicals, (2) exposure to side stream cigarette smoke, (3) prior use of cyclooxygenase (cox) inhibiting drugs, a

New life-saving treatments for Bladder cancer in clinical trial on Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults

Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells Ji-Fan Lin,1 Yi-Chia Lin,2 Te-Fu Tsai,2,3 Hung-En Chen,2 Kuang-Yu Chou,2,3 Thomas I-Sheng Hwang2–4 1Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, 2Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei, 3Division of Urology, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, 4Department of Urology, Taipei Medical University, Taipei, Taiwan Purpose: Cisplatin-based chemotherapy is the first line treatment for several cancers including bladder cancer (BC). Autophagy induction has been implied to contribute to cisplatin resistance in ovarian cancer; and a high basal level of autophagy has been demonstrated in human bladder tumors. Therefore, it is reasonable to speculate that autophagy may account for the failure of cisplatin single treatment in BC. This study investigated whether cisplatin induces autophagy and the mechanism involved using human BC

Cytology diagnosis: Malignant, consistent with a high grade metastatic transitional cell carcinoma. Biopsy of same mass diagnosis: Malignant, consistent with a high grade metastatic transitional cell carcinoma. The case was provided by Milstead Pathology, Conyers, GA.. ...

The Urology Group now offers a progressive approach to treating non-muscle invasive bladder cancer called Blue Light Cystoscopy with Cysview. Blue Light Cystoscopy with Cysview is a unique technology to detect and diagnose tumors in the bladder. Cysview causes abnormal cells to glow bright pink under a blue light. Better tumor visibility means a more complete tumor removal and a more thorough look during surveillance. As a result of outcomes in clinical trials, this technology is included in the bladder cancer guidelines published by the American Urological Association and the Society of Urologic Oncology.. The Urology Group has been using this technology since 2020 at Reston Hospital. Blue Light Cystoscopy is now also available at Inova Loudoun Hospital. Talk to your urologist to see if Blue Light Cystoscopy is right for you.. Print Page ...

Supplementary Material for: Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review

The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.

Front-line platinum-based combination chemotherapy leads to high response rates but suboptimum overall survival for patients with advanced transitional-cell carcinoma of the urothelium. Bevacizumab is being assessed in combination with platinum-based first-line chemotherapy in a large phase 3 trial. …

EAU 2019 the impact of blue light flexible cystoscopy, Cysview® non-muscle invasive bladder cancer (NMIBC), blue light cystoscopy at the time of TURBT to increase detection and decrease recurrence of bladder cancer, Blue Light Cystoscopy (BLC™) .

Although radiological tests provide important information about the kidneys and the ureters, cystoscopy is still the best method of evaluating the bladder and the urethra. The cystoscope, a long thin camera, is inserted through the urethra into the bladder.. Today, using flexible cystoscopes, most of these diagnostic procedures are performed in a urologists clinic with little or no discomfort. During the cystoscopy, the urologist will look through the cystoscope and make a note of anything in the bladder that may be abnormal. If a tumor or other abnormality is identified, the urologist will likely schedule you for a cystoscopy under anesthesia with bladder biopsy or transurethral resection of bladder tumor (TURBT).. Some urologist may have the ability to perform small bladder biopsies in the office. The tissue sample, or biopsy, is then sent to the pathologist for examination. A sample of the urine from the bladder is sent for analysis of the cells (called cytology) to determine if the urine ...

Learn about TECENTRIQ® (atezolizumab) for advanced urothelial carcinoma treatment, potential benefits and side effects of TECENTRIQ, and more. mUC Patient Indication and Safety Information What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: A type of bladder and urinary tract cancer called urothelial carcinoma. TECENTRIQ may be used when your bladder cancer: has spread or cannot be removed by surgery (advanced urothelial carcinoma), and you are not able to take chemotherapy that contains a medicine called cisplatin, or you have tried chemotherapy that contains platinum, and it did not work or is no longer working. It is not known if TECENTRIQ is safe and effective in children. The approval of TECENTRIQ in these patients is based on a study that measured response rate and duration of response. There is an ongoing study to confirm clinical benefit. Important Safety Information: What is the most important information about TECENTRIQ? TECENTRIQ can cause your immune system to attack

TY - JOUR. T1 - Changing Trends for Suicidal Death in Patients With Bladder Cancer. T2 - A 40+ Year Population-level Analysis. AU - Klaassen, Zachary. AU - Goldberg, Hanan. AU - Chandrasekar, Thenappan. AU - Arora, Karan. AU - Sayyid, Rashid K.. AU - Hamilton, Robert J.. AU - Fleshner, Neil E.. AU - Williams, Stephen B.. AU - Wallis, Christopher J.D.. AU - Kulkarni, Girish S.. N1 - Publisher Copyright: © 2018 Elsevier Inc. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2018/6. Y1 - 2018/6. N2 - To identify the demographic and clinical factors associated with suicidal death among patients with bladder urothelial carcinoma, patients diagnosed from 1973 to 2013 were identified in the Surveillance, Epidemiology, and End Results database. Using a competing risks model, factors associated with suicidal death included older age, unmarried status, white race, male gender, regional disease, living in the Southeast United States, and not undergoing a radical cystectomy. Background: ...

Initial experience of partial cystectomy with transurethral laparoscopic technique for bladder carcinoma, Congxiang Han, Jinyu Li, Xiacong Lin, Li Zhao, Zh